Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GRK6 | P43250 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25309572 | 1.00 | POLB (0.48) | POLBKMT2AMEN1SMN1; SMN2GRK6 | |
| SCHEMBL15973061 | 0.91 | KMT2A (0.50) | POLBKMT2AMEN1SMN1; SMN2ATM | |
| SCHEMBL30526810 | 0.89 | GRK6 (0.48) | POLBKMT2AMEN1SMN1; SMN2GRK6 | |
| SCHEMBL30526608 | 0.82 | POLQ (0.45) | KMT2AMEN1SMN1; SMN2GRK6HTT | |
| SCHEMBL25309871 | 0.82 | POLQ (0.45) | KMT2AMEN1SMN1; SMN2GRK6HTT | |
| SCHEMBL31325744 | 0.80 | KMT2A (0.52) | POLBKMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL6650250 | 0.78 | CTSV (0.52) | POLBKMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL6651351 | 0.78 | LMNA (0.52) | POLBKMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL570064 | 0.78 | TDP1 (0.57) | POLBKMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL6650235 | 0.77 | RORC (0.46) | POLBKMT2AMEN1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | BEIGENE, LTD. (KY) | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | POLQ, POLK, POLI | POLB 5/4885KMT2A 849/4885MEN1 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.